Daniel J. George, MD, on RCC: Results From the Alliance A031203 CABOSUN Trial

2018 Genitourinary Cancers Symposium
Tweet this page

Daniel J. George, MD, of Duke University Medical Center, discusses study findings on cabozantinib vs sunitinib for previously untreated patients with advanced renal cell carcinoma of intermediate or poor risk, in a subgroup analysis of progression-free survival and objective response rates (Abstract 582).

Jun

Today In Oncology

Eating a High-Quality Diet Could Decrease Cancer Survivors’ Risk of Death by 65%

Older Patients With Melanoma Fare Better on Anti–PD-1 Immunotherapy Than Younger Patients

Total Neoadjuvant Therapy for Borderline Resectable Pancreatic Adenocarcinoma

ASCO Guideline for Geriatric Oncology: Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy

FDA and EMA Accept Regulatory Submissions for Review of Talazoparib for Patients With Germline BRCA-Mutated Metastatic Breast Cancer

;